Interventional device developer Boston Scientific has received Food and Drug Administration marketing approval for its Taxus Express2 paclitaxel-eluting coronary stent system.
The Natick, MA-based company plans to launch the product in the U.S. immediately, and said it has ample inventory in all sizes. The Taxus product will use the Express2 coronary stent on the Maverick balloon catheter as its platform.
Boston Scientific introduced the Taxus system in Europe and other international markets in February 2003.
By AuntMinnie.com staff writers
March 5, 2004
Related Reading
Boston Scientific to build intercontinental distribution center, March 4, 2004
Boston Scientific, Guidant settle litigation, February 23, 2004
Boston Scientific gets Canadian approval, February 19, 2004
Boston Scientific expands Minnesota operations, February 18, 2004
Boston Scientific posts final 2003 results, February 2, 2004
Copyright © 2004 AuntMinnie.com
